Head-To-Head Comparison: AbCellera Biologics (NASDAQ:ABCL) versus Ascletis Pharma (OTCMKTS:ASCLF)

AbCellera Biologics (NASDAQ:ABCL) and Ascletis Pharma (OTCMKTS:ASCLF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares AbCellera Biologics and Ascletis Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-463.77%	-13.40%	-10.44%
Ascletis Pharma	N/A	N/A	N/A

Institutional and Insider Ownership

61.4% of AbCellera Biologics shares are held by institutional investors. 32.5% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AbCellera Biologics and Ascletis Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$33.05 million	23.04	-$146.40 million	($0.52)	-4.98
Ascletis Pharma	N/A	N/A	N/A	N/A	N/A

Ascletis Pharma has lower revenue, but higher earnings than AbCellera Biologics.

Analyst Recommendations

This is a summary of current ratings and target prices for AbCellera Biologics and Ascletis Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	0	1	5	0	2.83
Ascletis Pharma	0	0	0	0	N/A

AbCellera Biologics presently has a consensus price target of $14.20, suggesting a potential upside of 448.26%. Given AbCellera Biologics’ higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Ascletis Pharma.

Summary

AbCellera Biologics beats Ascletis Pharma on 5 of the 8 factors compared between the two stocks.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People’s Republic of China.